169 related articles for article (PubMed ID: 20179914)
21. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
22. Aliskiren, the future of renin-angiotensin system blockade?
Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
24. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
[TBL] [Abstract][Full Text] [Related]
25. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
27. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
28. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
[TBL] [Abstract][Full Text] [Related]
29. Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
Barkoudah E; van Thiel BS; Fisher ND; Gregg RA; Danser AH; Moukarbel GV; Hollenberg NK
J Hypertens; 2016 May; 34(5):935-41. PubMed ID: 26882043
[TBL] [Abstract][Full Text] [Related]
30. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
Sealey JE; Laragh JH
Am J Hypertens; 2007 May; 20(5):587-97. PubMed ID: 17485026
[TBL] [Abstract][Full Text] [Related]
31. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
Dieterle W; Corynen S; Mann J
Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
[TBL] [Abstract][Full Text] [Related]
33. Aliskiren: renin inhibitor for hypertension management.
Cheng JW
Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
[TBL] [Abstract][Full Text] [Related]
34. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
[TBL] [Abstract][Full Text] [Related]
35. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren.
Ichihara A; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Bokuda K; Itoh H
J Pharmacol Sci; 2010; 113(4):296-300. PubMed ID: 20675959
[TBL] [Abstract][Full Text] [Related]
36. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
38. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
39. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V
Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880
[TBL] [Abstract][Full Text] [Related]
40. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
